Hepatoprotection as a way to increase the hypolipidemic efficacy of combined statin therapy with ezetimibe in patients with ischemic heart disease in combination with metabolically associated steatohepatitis
Ukrainian Therapeutical Journal · 30.06.2026 · (2) · 12-16
DOI: 10.30978/utj2026-2-12 ↗Kurz gefasst
Fachartikel in der Zeitschrift Ukrainian Therapeutical Journal, online erschienen am 30.06.2026. Verfasst von I. M. Skrypnyk und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-ND 4.0).
Abstract (Originalsprache)
Objective — to identify ways to optimize statin therapy in patients with ischemic heart disease complicated by metabolically associated steatohepatitis (MASH) during the post-infarction period in order to improve efficacy and ensure maximum safety. Materials and methods. 82 patients with IHD and concomitant MASH who had experienced acute coronary syndrome within the past 4 — 6 months were examined. The mean age was 56.5±4.7 years. Men predominated among the patients (62 (75.6%)). At the initial stage, patients received standard therapy: atorvastatin (40 mg/day) in combination with ezetimibe (10 mg/day). After 3 months of follow-up, 59 (72%) patients had not achieved the target low-density lipoprotein cholesterol level (< 1.4 mmol/L). This group was additionally prescribed ursodeoxycholic acid (UDCA) at a dose of 13 mg/kg of body weight per day.
Results
The combination of atorvastatin 40 mg/day with ezetimibe 10 mg/day and UDCA 13 mg/kg of body weight per day allows for a significant increase in the hypolipidemic efficacy of statin therapy in the conditions of combination of IHD with MASH by normalizing the activity of indicators of the functional state of the liver (reducing cytolytic syndrome activity) and through the pleiotropic lipid-lowering mechanisms of UDCA. Taking atorvastatin at a dose of 40 mg/day and ezetimibe at a dose of 10 mg/day in combination with UDCA at a dose of 13 mg/kg of body weight per day is one of the priority approaches for optimizing long-term statin therapy in patients with IHD combined with MASH, as evidenced by its marked clinical and biochemical efficacy and high safety profile.
Conclusions
The inclusion of UDCA in the complex treatment of patients with very high cardiovascular risk with liver pathology is a reasonable step to achieve lipid profile targets and increase the safety of long-term statin therapy.
Zitieren
APA
Skrypnyk, I. M., Dubrovinska, T. V., & Neporada, K. S. (2026). Hepatoprotection as a way to increase the hypolipidemic efficacy of combined statin therapy with ezetimibe in patients with ischemic heart disease in combination with metabolically associated steatohepatitis. Ukrainian Therapeutical Journal, 12-16. https://doi.org/10.30978/utj2026-2-12
Vancouver
Skrypnyk IM, Dubrovinska TV, Neporada KS. Hepatoprotection as a way to increase the hypolipidemic efficacy of combined statin therapy with ezetimibe in patients with ischemic heart disease in combination with metabolically associated steatohepatitis. Ukrainian Therapeutical Journal. 2026:12-16. doi:10.30978/utj2026-2-12
BibTeX
@article{Skrypnyk2026,
author = {Skrypnyk, I. M. and Dubrovinska, T. V. and Neporada, K. S.},
title = {Hepatoprotection as a way to increase the hypolipidemic efficacy of combined statin therapy with ezetimibe in patients with ischemic heart disease in combination with metabolically associated steatohepatitis},
journal = {Ukrainian Therapeutical Journal},
year = {2026},
number = {2},
pages = {12--16},
doi = {10.30978/utj2026-2-12}
}
EUVIMED